Doxazosin Tablet
Product Images NDC 68071-4273

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 68071-4273). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4273 3

68071 4273 3
NuCare Pharmaceuticals Inc. has produced Doxazosin 2mg tablets with lots #000000 and #006000. The tablets are yellow and cream-colored, scored and round. They are available in packs of 30 tablets, each containing 2 mg of Doxazosin Mesylate USP. The expiration date is 00-00. The FDA regulates NuCare Pharmaceuticals Inc. Customers are advised to store the drug at a controlled temperature (59-86°F) and to contact their doctor for advice on possible side effects. If needed, they can report side effects to FDA at 1.800-FDA-1085. The product carries a warning to keep out of the reach of children.*
FDA Label Image

Table 1 (Doxazosin Fig1)

Table 1 (Doxazosin Fig1)
This is a table summarizing effectiveness data in placebo-controlled trials. The table shows the maximum flow rate, symptom score, baseline, and change in baseline for several studies. Study 1 had a titration of maximum dose of Vatinum Fo, while study 2 had a titration to a fixed dose of 14 weeks. Study 3 had a fixed dose of 12 weeks. The questionnaire used was the AUA questionnaire with a range of 0 to 30 in studies 1 and 3. Modified Boyarsiy questionnaire with a range of 7 to 39 in study 2. The endpoint change is different for the fixed-dose eye. There are several different dosages and drugs that were used in the studies.*
FDA Label Image

Figure 1 – Study 1 (Doxazosin Fig2)

Figure 1 – Study 1 (Doxazosin Fig2)
This appears to be a table or chart showing the mean increase in maximum urinary flow rate and mean change in total symptom score from baseline for a group of subjects receiving a treatment compared to a placebo. The duration of treatment is also indicated. There is a note mentioning something about a medication called Doxazosi Titaton up to a maximum dose of 8 mg.*
FDA Label Image

Chemical Structure (Doxazosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.